Witnessing the stock’s movement on the chart, on Tuesday, Esperion Therapeutics Inc (NASDAQ: ESPR) set off with pace as it heaved 2.68% to $2.30, before settling in for the price of $2.24 at the close. Taking a more long-term approach, ESPR posted a 52-week range of $1.58-$3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 7.64% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 23.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 85.28%. This publicly-traded company’s shares outstanding now amounts to $195.44 million, simultaneously with a float of $195.08 million. The organization now has a market capitalization sitting at $465.32 million. At the time of writing, stock’s 50-day Moving Average stood at $2.42, while the 200-day Moving Average is $2.24.
Esperion Therapeutics Inc (ESPR) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – Specialty & Generic industry. Esperion Therapeutics Inc’s current insider ownership accounts for 0.99%, in contrast to 65.84% institutional ownership. According to the most recent insider trade that took place on Dec 17 ’24, this organization’s Chief Financial Officer sold 3,245 shares at the rate of 2.42, making the entire transaction reach 7,866 in total value, affecting insider ownership by 240,691. Preceding that transaction, on Dec 17 ’24, Company’s Chief Commercial Officer sold 2,234 for 2.43, making the whole transaction’s value amount to 5,426. This particular insider is now the holder of 160,121 in total.
Esperion Therapeutics Inc (ESPR) Earnings and Revenue Records
Esperion Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 85.28% and is forecasted to reach 0.22 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 16.90% through the next 5 years, which can be compared against the 23.09% growth it accomplished over the previous five years trading on the market.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Let’s observe the current performance indicators for Esperion Therapeutics Inc (ESPR). It’s Quick Ratio in the last reported quarter now stands at 1.37. The Stock has managed to achieve an average true range (ATR) of 0.29. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.57.
In the same vein, ESPR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.66, a figure that is expected to reach -0.13 in the next quarter, and analysts are predicting that it will be 0.22 at the market close of one year from today.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Going through the that latest performance of [Esperion Therapeutics Inc, ESPR]. Its last 5-days volume of 4.07 million was inferior to the volume of 6.35 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 33.69% While, its Average True Range was 0.29.
Raw Stochastic average of Esperion Therapeutics Inc (ESPR) in the period of the previous 100 days is set at 30.51%, which indicates a major rise in contrast to 21.90% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 141.09% that was higher than 90.22% volatility it exhibited in the past 100-days period.
